Sjogren M H, Dusheiko G M, Kew M C, Song E
Department of Virus Diseases, Walter Reed Army Institute of Research, Washington, DC.
Am J Trop Med Hyg. 1988 Dec;39(6):582-5. doi: 10.4269/ajtmh.1988.39.582.
Sera from 102 black patients with primary hepatocellular carcinoma (PHC) and hepatitis B surface antigenemia were tested for immunoglobulin M antibody against hepatitis B core (IgM anti-HBc), hepatitis B e antigen (HBeAg), and hepatitis B viral (HBV) DNA. Their prevalences were compared to those of a control group of 124 age and sex matched black HBV carriers without tumor. IgM anti-HBc was present in 68.6%, HBeAg in 32.3%, and HBV-DNA in 26.7% of the patients. In the control population, IgM anti-HBc was present in 45%, HBeAg was detected in 3.2%, and HBV-DNA in 25.8%. We conclude that IgM anti-HBc is present appreciably more often than either HBeAg or HBV-DNA in patients with PHC. HBeAg or IgM anti-HBc in serum of HBsAg positive carriers may predict an added risk of PHC development in South African blacks.
对102例患有原发性肝细胞癌（PHC）且乙肝表面抗原血症的黑人患者的血清进行了乙肝核心抗体免疫球蛋白M（IgM抗-HBc）、乙肝e抗原（HBeAg）和乙肝病毒（HBV）DNA检测。将这些指标的患病率与124名年龄和性别匹配、无肿瘤的黑人HBV携带者对照组进行比较。患者中，68.6%存在IgM抗-HBc，32.3%存在HBeAg，26.7%存在HBV-DNA。在对照人群中，45%存在IgM抗-HBc，3.2%检测到HBeAg，25.8%存在HBV-DNA。我们得出结论，在PHC患者中，IgM抗-HBc的出现频率明显高于HBeAg或HBV-DNA。HBsAg阳性携带者血清中的HBeAg或IgM抗-HBc可能预示南非黑人发生PHC的额外风险。
